Illumina's mission centers on enhancing human health through genomic advancements, primarily via their sequencing machines. These devices play a crucial role in various fields, from pediatric diagnostics to cancer treatment and even agriculture. The acquisition of Grail exemplifies Illumina's strategy to accelerate emerging markets while balancing core business growth with innovative product development.
